Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Oct 06, 2020 10:00 AM - Oct 07, 2020 5:25 PM

(US Eastern Standard Time)

Fort Washington, PA 19034

Biosimilars Conference

Session 3: Streamlining Biosimilar Clinical Development

Session Chair(s)

Cecil J. Nick, MS

Cecil J. Nick, MS

FTOPRA, Vice President (Technical)

Parexel Consulting, United Kingdom

This session addresses ways in which the clinical development of biosimilars can be streamlined exploring issues at to what extent current study designs contribute data that add value to the biosimilarity assessment. In particular is therapeutic equivalence adding value and to what extent CMC, PK and immunogenicity data can address therapeutic effect without the need for direct therapeutic equivalence trials.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Appraise the clinical data requirements to support determination of biosimilarity
  • Justify situations where therapeutic equivalence data may not be required
  • Design and justify an optimal clinical development program to support determination of biosimliarity

Speaker(s)

Martin  Schiestl, PhD

The Path Towards a Tailored Clinical Biosimilar Development

Martin Schiestl, PhD

Sandoz GmbH, Austria

Global Head Regulatory Affairs Policy

Andrea  Laslop, MD

Regulatory Expectations for Supporting Efficacy, Safety, and Immunogenicity of Biosimilars in the Clinic

Andrea Laslop, MD

Austrian Medicines and Medical Devices Agency, Austria

Head of Scientific Office

Barbara K Finck, MD, RN

Applying Experiences with Udencya to Streamline Future Biosimilar Clinical Development

Barbara K Finck, MD, RN

Coherus, United States

CMO

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.